Critical Care

official impact factor 4.60

This article is part of the supplement: Optimizing the use of carbapenems in the face of increasing Gram-negative resistance

Highly Access Review

The role of carbapenems in initial therapy for serious Gram-negative infections

James J Rahal

Critical Care 2008, 12(Suppl 4):S5 doi:10.1186/cc6821

No comments have yet been made on this article.

Post a comment